4Basebio

Two non-executive directors of 4basebio acquired shares in market transactions. Dr. Heikki Lanckriet purchased 3,000 ordinary shares on 10 February at 575.82 pence, bringing his holding to 1,122,688 shares (7.23% of the issued share capital). Hansjörg Plaggemars acquired 1,000 ordinary shares at 585 pence on behalf of his wife; his aggregate holding after the purchase is 7,667 shares (0.05%). The issued share capital comprises 15,538,518 ordinary shares. » More on de.investing.com

4basebio has appointed Dr. Amy Walker, formerly COO, as its new CEO. She succeeds Dr. Heikki Lanckriet, who will remain on the supervisory board and will drive the spin‑out of the Hermes platform. The Hermes platform is intended to enable DNA delivery via nanoparticles and to serve as the basis for a separately financed therapeutics business. CFO David Roth is leaving the company but will remain as an adviser during the search for a successor; management had already announced several senior leadership appointments. » More on de.investing.com

4basebio’s stock climbed 6.9% after a leading global pharma partner began dosing patients in phase‑I/II studies following FDA approval, using the opDNA® template for an mRNA product. The study builds on a supply agreement from April 2024 and follows 4basebio’s GMP certification for its production facility in April 2025. The company highlights advantages of synthetic opDNA over plasmid DNA such as lower costs, higher purity and faster, scalable production, which can shorten development times for cell and gene therapies. » More on de.investing.com